Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the needs of people living with or affected by NCDs, including reducing out-of-pocket costs and ensuring affordable access to NCD medicines, products, and services.
Geneva, January 5, 2026 – The International Generic and Biosimilar Medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, announced today that Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada, has assumed the role of IGBA Chair for 2026. He succeeds Shinichiro Hirose, Director of International Affairs at the Japan Generic Medicines Association (JGA).
A research report resulting from a collaboration between the University of Maryland and University of Michigan (USA) delivers a critical set of recommendations emphasizing the urgent need for policies that foster single global development of off patent medicines.
- The IGBA CEO Advisory Committee: Patient Access, Industry Value, and Global Cooperation in a Reshaping World (December 2025)
- WHO Director General Reaffirms the Critical Role of Quality-Assured Generic and Biosimilar Medicines at WHO Global Forum for Public Procurement of Health Products (November 2025)
- Global Biosimilars Week 2025 Launches: Advancing Health Equity Through Wise Investment in Access to Medicines (November 2025)
- IGBA at UNGA Side Events (September 2025)
